関連する実験動画
Updated: Sep 9, 2025

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
347
重度のうつ病と併発性肥満の臨床管理
Nils Opel1, Ruth Hanssen2, Lavinia A Steinmann3
1Department of Psychiatry and Neuroscience, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, Berlin, Germany; German Center for Mental Health (DZPG), Partner Site Berlin-Potsdam, Germany.
The lancet. Psychiatry
|August 31, 2025
まとめ
重度のうつ病と肥満は 複雑な関係を持ち 治療に影響を与えるサイクルを作り出します このレビューは,併発性うつ病と肥満の管理のための統合された枠組みを提供します.
科学分野:
- 精神科
- 内分泌学
- 公衆衛生
背景:
- 肥満は重度のうつ病 (MDD) の共同疾患であり,その予後に大きな影響を与える.
- MDDと肥満の双方向関係は 患者と臨床医にとって 難しいフィードバックループを形成します
- 不効率な管理は,学際的な協力の断片化と知識の不足から生じます.
研究 の 目的:
- 併発性メジャーうつ病と肥満の管理に関する現在の証拠を統合する.
- 心理的および代謝的要因を統合したリスクの分層化とモニタリングの枠組みを提案する.
- この複雑な患者集団の 臨床的意思決定を導くために
主な方法:
- 鬱病と肥満に関する既存の研究をまとめています
- 薬学,心理療法,ライフスタイルへの介入に関する証拠が検討される.
- 統合されたリスク評価とモニタリングの枠組みが提示されています.
主要な成果:
- 現在の証拠は 鬱症状と体重管理の両方を対象とした介入を支持しています
- 運動や食事の変更など ライフスタイルの戦略も重要です
- 薬物療法や心理療法によって 鬱の症状を和らげ 体重をコントロールできます
結論:
- 統合された学際的なアプローチは,併発性メジャーうつ病と肥満の効果的な治療に不可欠です.
- 心理的および代謝的モニタリングを組み合わせることで 臨床的意思決定が促進されます
- 医療の最適化には 医療従事者の実践的な指導が必要です
関連する概念動画
Antidepressant Drugs: MAOIs and Other Agents
340
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
340
Depressive Disorders: MDD and Dysthymia
208
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
208
Depression: Overview
331
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
331
Binge Eating Disorders
168
Binge eating disorder is a significant mental health condition characterized by recurrent episodes of excessive food consumption within a short period, accompanied by a perceived loss of control over eating behavior. Unlike occasional overeating, binge eating disorder is marked by distressing emotions such as guilt, shame, and anxiety following binge episodes. The disorder affects individuals across different ages and backgrounds, with profound implications for physical and psychological...
168
Antidepressant Drugs: Overview
741
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
741
Diabetes: Management and Pharmacotherapy
354
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
354

